Immunotherapy of Malignant Melanoma with Tumor Lysate-Pulsed Autologous Monocyte-Derived Dendritic Cells
Yonsei Medical Journal
; : 990-998, 2011.
Artículo
en Inglés
| WPRIM (Pacífico Occidental)
| ID: wpr-30290
Biblioteca responsable:
WPRO
ABSTRACT
PURPOSE:
Dendritic cell (DC) vaccination for melanoma was introduced because melanoma carries distinct tumor-associated antigens. The purpose of this study was to investigate the efficacy and safety of DC vaccination for melanoma in Korea. MATERIALS ANDMETHODS:
Five patients with stage IV and one with stage II were enrolled. Autologous monocyte-derived DCs (MoDCs) were cultured and pulsed with tumor-lysate, keyhole limpet hemocyanin, and cytokine cocktail for mature antigen-loaded DC. DC vaccination was repeated four times at 2-week intervals and 2-4x107 DC were injected each time.RESULTS:
Reduced tumor volume was observed by PET-CT in three patients after DC vaccination. Delayed type hypersensitivity responses against tumor antigen were induced in five patients. Tumor antigen-specific IFN-gamma-producing peripheral blood mononuclear cells were detected with enzyme-linked immunosorbent spot in two patients. However, the overall clinical outcome showed disease progression in all patients.CONCLUSION:
In this study, DC vaccination using tumor antigen-loaded, mature MoDCs led to tumor regression in individual melanoma patients. Further standardization of DC vaccination protocol is required to determine which parameters lead to better anti-tumor responses and clinical outcomes.
Texto completo:
Disponible
Base de datos:
WPRIM (Pacífico Occidental)
Asunto principal:
Células Dendríticas
/
Ensayo de Inmunoadsorción Enzimática
/
Monocitos
/
Resultado del Tratamiento
/
Citometría de Flujo
/
Inmunoterapia
/
Melanoma
Tipo de estudio:
Guía de práctica clínica
Límite:
Humanos
Idioma:
Inglés
Revista:
Yonsei Medical Journal
Año:
2011
Tipo del documento:
Artículo